Patients

• Eisai and Biogen announced positive top-line results from CLARITY AD trial extension on April 7, 2026, with lecanemab reducing cognitive decline by 27% over 18 months in 1,795 US patients. • Drug cleared 59% more amyloid plaques vs. placebo, with ARIA side effects in 12.6% of participants; full data at June AD/PD conference. • Approval could expand to mild cases, addressing 6.7 million US Alzheimer's sufferers; analysts predict $2.4 billion annual sales.

People encouraged to ‘come forward as normal’ when BMA members begin industrial action over pay on TuesdayThe NHS is urging patients not to put off seeking the care they need when resident doctors press ahead with strike action from Tuesday, a stoppage that the health secretary has called “disappointing”.Tens of thousands of resident doctors in England are to stage a six-day strike after the government took a key part of its offer off the table. Continue reading...

People receive rehab only three to four days a week in hospital – and one to two days once they are discharged, data suggestsThe NHS is failing stroke patients and limiting their chances of recovery because of a shortage of rehabilitation care staff, health leaders have said.More people are surviving strokes than ever before in the UK. But their hopes of getting better are being dashed because of a lack of physiotherapists and other specialist staff, according to the Chartered Society of Physiotherapy and the Association of Chartered Physiotherapists in Neurology. Continue reading...